iShares MSCI Taiwan ETF vs Vir Biotechnology Inc. Common Stock — how do they compare? iShares MSCI Taiwan ETF trades at $107.8 (market cap $12.49B), while Vir Biotechnology Inc. Common Stock trades at $10.2 (market cap $1.80B). The key difference: iShares MSCI Taiwan ETF is far larger — about 6.9× Vir Biotechnology Inc. Common Stock's market cap, and iShares MSCI Taiwan ETF is more actively traded (5,965,495 versus 1,782,836). Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Taiwan ETF for 53 Days and Vir Biotechnology Inc. Common Stock for 0 Days on average.
| EWT | VIR | |
|---|---|---|
Market Cap | $12.49B | $1.80B |
Volume | 5,965,495 | 1,782,836 |
Sector | Broad Market / Factor | Health |
52-Week High | $118.00 | $11.78 |
52-Week Low | $60.03 | $5.12 |
Typical Hold Time | 53 Days | 0 Days |
Enterprise Value | — | $1.36B |
Signals from Pluang's Aura AI — not financial advice
EWT (iShares MSCI Taiwan ETF) trades at $113.46, down 0.71% on the day, with technical indicators showing a bullish trend from moving averages while oscillators remain neutral. The ETF maintains strong exposure to Taiwan's semiconductor sector, particularly TSMC, which represents 22.5% of holdings. Recent news highlights Taiwan's strategic position in AI chip manufacturing with companies planning $20 billion in US investments.
The ETF offers exposure to Taiwan's dominant semiconductor industry but faces significant geopolitical risks. Strong AI-driven fundamentals and reasonable tech valuations support upside potential, though China-Taiwan tensions represent a persistent overhang. Institutional interest remains positive with Bank of America increasing its stake by 22.4% in the latest quarter.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
EWT tracks the MSCI Taiwan 25/50 Index, providing targeted exposure to large and mid-cap companies in Taiwan. It is heavily concentrated in the information technology sector, serving as a liquid instrument for investors seeking a single-country view of Taiwan's export-oriented and tech-driven economy.
Read more on EWT →Vir Biotechnology, Inc. is a US clinical-stage biopharmaceutical company that develops monoclonal antibody-based medicines to treat and prevent serious infectious diseases.
Read more on VIR →